Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company developing therapies for autoimmune thyroid diseases. Its principal program is YB-101, also known as GenSci098 or GS-098, a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor for Graves’ disease and thyroid eye disease; the company also evaluates legacy programs for potential monetization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical development of a humanized TSHR antibody for Graves’ disease and thyroid eye disease.
Development activities targeting the autoimmune mechanisms underlying Graves’ disease.
Exploration of a clinical development plan for thyroid eye disease, an extra-thyroidal autoimmune condition.
Repibresib and VYN202 assets that may be sold, licensed, transferred, or otherwise monetized.
Asiakkaat
Yarrow has no approved commercial products and therefore does not currently serve a conventional product-revenue customer base. Its eventual customers would include patients with Graves’ disease or thyroid eye disease, prescribing physicians, healthcare systems, and payers seeking targeted treatment options. Biotechnology and pharmaceutical companies are also potential counterparties for licensing, development, manufacturing, or asset-monetization transactions.
Potential end users of YB-101 for treatment of TSHR-driven autoimmune thyroid disease.
Potential end users of YB-101 if the company advances a TED development plan.
Endocrinologists and ophthalmologists who would select and prescribe approved therapies.
Insurers and providers that would assess reimbursement, clinical value, and treatment economics.
Potential licensees or transaction counterparties for YB-101 and legacy development programs.
Strategia
Yarrow’s strategy centers on advancing YB-101 as a potentially first-in-class TSHR antibody for Graves’ disease and evaluating its application in thyroid eye disease. The company must convert a licensed clinical-stage asset into an executable development program while building capabilities in clinical operations, regulatory affairs, manufacturing, and eventual commercialization. Repibresib and VYN202 are non-core assets that may be monetized rather than receiving significant internal resources.
Clinical progress is the principal driver of future product value and regulatory optionality.
The company has limited operating history and has not demonstrated commercial-scale manufacturing capability.
Transactions could provide value or funding without diverting resources from YB-101.
The GenSci license provides rights outside Greater China and creates a basis for global development and partnering.
Maantiede
Yarrow is headquartered and organized in the United States, while its lead asset is licensed from Changchun Genescience Pharmaceutical Company for development, manufacturing, and commercialization outside Greater China. The company’s operations are internationally exposed through the license territory, clinical-development activities, regulatory requirements, and potential commercialization markets, but the available reports do not disclose country-level revenue.
Riskit
Yarrow’s value depends heavily on one clinical-stage asset, with no approved products, completed pivotal trials, or established commercial operations. Clinical, regulatory, manufacturing, financing, and competitive failures could delay or prevent commercialization, while the GenSci license creates dependence on contractual rights and an external technology partner. The company also faces execution risk because it has limited experience initiating and completing clinical trials as the combined business.
- Regulatory approval failureVaikutus: KriittinenTodennäköisyys: Korkea
The company has not demonstrated an ability to obtain approval for YB-101 or another product.
Kohdistuu: U.S. and international regulators
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
YB-101 may fail to demonstrate safety or efficacy in Graves’ disease or thyroid eye disease.
Kohdistuu: Primary pipeline asset
- Limited clinical execution experienceVaikutus: KorkeaTodennäköisyys: Korkea
Yarrow has limited experience initiating, conducting, and completing preclinical or clinical studies.
Kohdistuu - Capital requirementsVaikutus: KorkeaTodennäköisyys: Korkea
Clinical development, regulatory work, manufacturing, and general operations require substantial additional funding before commercialization.
Kohdistuu: Cash runway and future financing
- Manufacturing and supply riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has not demonstrated commercial-scale manufacturing or the ability to arrange it through third parties.
Kohdistuu: Biologic production and clinical supply
- Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Large pharmaceutical companies, biotechnology firms, academic institutions, and future therapies may compete for patients and market access.
Kohdistuu: Autoimmune thyroid disease markets
- License and partner dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
YB-101 is licensed from GenSci, making development rights and performance partly dependent on an external counterparty.
Kohdistuu: Territories outside Greater China
Kirjanpito
Harkinnanvaraiset erätAccrual estimates for clinical, laboratory, and development services affect reported R&D expenses and liabilities.
Vaikutus: Changes in estimated work performed can shift quarterly expenses.
The GenSci license may involve upfront, milestone, royalty, or other contractual obligations requiring judgment in recognition and disclosure.
Vaikutus: Payments and obligations can affect assets, expenses, or future cash requirements.
Options and other equity awards require valuation assumptions and create non-cash operating expenses.
Vaikutus: Expense timing affects reported losses and equity.
Clinical setbacks, regulatory outcomes, or changes in commercial prospects may affect the recoverability of acquired or licensed assets.
Vaikutus: Potential impairment charges could materially reduce reported assets and earnings.
The company has no approved commercial products and historically reported no corresponding product revenue, limiting revenue-recognition complexity.
Vaikutus: Future licensing, collaboration, royalty, or product revenue may introduce timing and contract-estimate judgments.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Gyre Therapeutics, Inc
GYRE · Pharmaceutical Preparations
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases.
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Viridian Therapeutics, Inc.
VRDN · Pharmaceutical Preparations
Viridian Therapeutics is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and rare diseases.
Päivitetty: 24.9.2026